squamous-cell-carcinoma

Documents about squamous-cell-carcinoma

• Kindlin-1 loss disrupts vascular and extracellular matrix organisation to sustain hypoxia in cutaneous squamous cell carcinoma#387676Europe PMC
• Biomarkers Predictive of Immunotherapy Efficacy in Head and Neck Squamous Cell Carcinoma: Current Insights and Future Perspectives.#402634NCBI PubMed Central
• Specificity and Sensitivity of Circulating Tumor HPV-DNA in Patients with HPV-Positive Oropharyngeal Squamous Cell Carcinoma.#409335NCBI PubMed Central
• Study of ALE.C04 in Patients With Head and Neck Cancer#411399ClinicalTrials.gov
• Foundation model-enhanced multimodal radiomics for predicting response to chemo-immunotherapy in advanced lung squamous cell carcinoma.#427711NCBI PubMed Central
• Predictive and mechanistic insights of GLTP on survival in patients with head and neck squamous cell carcinoma.#440709NCBI PubMed Central
• Induction and Maintenance Treatment With PARP Inhibitor and Immunotherapy in HPV-negative HNSCC#451474ClinicalTrials.gov
• Camrelizumab as a Maintenance Therapy After Chemoradiation in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma#474783ClinicalTrials.gov
• Peripheral Blood Biomarkers for Predicting the Efficacy of Neoadjuvant Immunochemotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma.#483370NCBI PubMed Central
• Trajectory Analysis of NLR and Its Association With Efficacy of Immunochemotherapy in ESCC.#640577ClinicalTrials.gov
• Targeting NAT10 Activates Tumor-Intrinsic Immunity and Suppresses Tumor Progression in Head and Neck Squamous Cell Carcinoma#660917bioRxiv / medRxiv
• A Study of ALKS 4230 (Nemvaleukin Alfa) With Pembrolizumab in Head and Neck Cancer#668815ClinicalTrials.gov
• PD 0332991 and Cetuximab in Patients With Incurable SCCHN#801855ClinicalTrials.gov
• Immunotherapy Combined With Chemoradiotherapy for First-line Treatment of Esophageal Squamous Cell Carcinoma（ChinECR）#802422ClinicalTrials.gov
• Characterising Metastatic Penile Cancer Using Molecular Imaging - Hybrid MRI-PET [MRI-PET]#804337ClinicalTrials.gov
• Case Review of Patients With Betel Nut-induced Oral Cancer Treated With Pembrolizumab and Cetuximab#806966ClinicalTrials.gov
• A Phase II Study to Evaluate Low-Dose Fractionated Radiotherapy (LDFRT)#839469ClinicalTrials.gov
• Differential Mobility Spectrometry (DMS) Based Oral Tumor Analysis#854147ClinicalTrials.gov
• Complications and Recurrences After Mohs Micrographic Surgery and Slow Mohs#803968ClinicalTrials.gov
• Acitretin in Preventing Skin Cancers in Patients With Previously Treated Skin Cancers Who Have Undergone Organ Transplantation#833077ClinicalTrials.gov
• Pilot Trial of E Cigarettes in Pts Diagnosed With Cancer of the Head, Neck, and Lung#806179ClinicalTrials.gov
• A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies#810763ClinicalTrials.gov
• GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma#870624ClinicalTrials.gov
• SCION: SABR and Checkpoint Inhibition of NSCLC#881945ClinicalTrials.gov
• Reflectance Confocal Microscopy of Wounds During Moh's Surgery: Feasibility Testing of a Mosaicing Algorithm for Intraoperative Imaging of Cancer Margins#884806ClinicalTrials.gov
• The Notch1/Delta-like-4 axis is crucial for the initiation and progression of oral squamous cell carcinoma#10085bioRxiv / medRxiv
• Linking metabolism and metastasis: elevated α-hydroxybutyric acid in oral squamous cell carcinoma patients with lymph node metastasis.#67468NCBI PubMed Central
• Anti-SIA-cIgG enhances chemotherapy effectiveness through PTPN13-regulated tumor stemness in head and neck squamous cell carcinoma.#135798NCBI PubMed Central
• Selected Chemotherapy Combined Immunotherapy Treated High Risk Patient After NCRT in Resected Locally Advanced ESCC#162460ClinicalTrials.gov
• Association of stromal tumor infiltrating lymphocytes and body mass index with prognosis in esophageal squamous cell carcinoma patients.#185921NCBI PubMed Central
• PET/CT-Guided Neoadjuvant Tislelizumab plus Chemotherapy/Chemoradiotherapy for Resectable Esophageal Squamous Cell Carcinoma: RATIONALE-213 Final Analysis.#193779NCBI PubMed Central
• Urban-rural disparities in survival of Chinese esophageal squamous cell carcinoma: a cohort study of 133,064 cases.#340695NCBI PubMed Central
• Tumour-to-tumour metastasis: head and neck squamous cell carcinoma to enchondroma#368919Springer Nature OA
• FKBP10 may affect the malignant phenotype of oral squamous cell carcinoma cells through the ECM/WNT signaling pathway.#404383NCBI PubMed Central
• Study of Pembrolizumab Combined with Chemotherapy in the First Line Therapy for R/M HNSCC in China#417529ClinicalTrials.gov
• Pembrolizumab Combined With Preoperative Chemotherapy (Albumin Paclitaxel+Carboplatin) Neoadjuvant Therapy for Resectable Locally Advanced (Stage II/III) Esophageal Squamous Cell Carcinoma#463707ClinicalTrials.gov
• Integrative transcriptomic analysis identifies shared coding and non-coding biomarkers in tongue squamous cell carcinoma across diverse populations.#610273NCBI PubMed Central
• PREVALENCE OF HUMAN PAPILLOMAVIRUS IN ORAL AND OROPHARYNGEAL SQUAMOUS CELL CARCINOMA: A SYSTEMATIC REVIEW AND META-ANALYSIS#619382CyberLeninka
• Genetic insights into lung squamous cell carcinoma: how TP53 and CSMD3 co-mutations shape prognosis and immune response.#685605NCBI PubMed Central
• DAHANCA 24: Prognostic Value of 18F-FAZA in Head and Neck Squamous Cell Carcinoma (HNSCC)#845608ClinicalTrials.gov
• Navigation for Timely Adjuvant Therapy for Patients With Locally Advanced HNSCC#890045ClinicalTrials.gov
• A Study of Lazertinib as Consolidation Therapy in Patients With Locally Advanced, Unresectable, EGFR-Mutant Non-Small Cell Lung Cancer (Stage III) Following Chemoradiation Therapy#898594ClinicalTrials.gov
• Identification of Predictive Factors for the Response to Anti-Programmed Cell Death Protein 1 (PD1) Immunotherapy in Head and Neck Squamous Cell Carcinoma#208439ClinicalTrials.gov
• Study to Test the Safety and Tolerability of PF-07257876 in Participants With Selected Advanced Tumors.#208451ClinicalTrials.gov
• Expression and clinical significance of LTA4H in esophageal squamous cell carcinoma#343161Figshare
• Evaluation of [18F]AlF-NOTA-PCP2 PET/CT for PD-L1 Detection in Malignant Tumors#448280ClinicalTrials.gov
• Identifying the Predictive Factors of Response to PD-1 or PD-L1 Antagonists#842712ClinicalTrials.gov
• PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors#843077ClinicalTrials.gov
• Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors#824951ClinicalTrials.gov
• Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers#828464ClinicalTrials.gov